Last reviewed · How we verify
Low-dose furosemide
Low-dose furosemide inhibits the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, reducing sodium reabsorption and promoting diuresis.
Low-dose furosemide inhibits the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, reducing sodium reabsorption and promoting urinary sodium and water excretion. Used for Edema associated with congestive heart failure, Edema associated with hepatic cirrhosis, Edema associated with renal disease.
At a glance
| Generic name | Low-dose furosemide |
|---|---|
| Sponsor | Larissa University Hospital |
| Drug class | Loop diuretic |
| Target | Na-K-2Cl cotransporter (NKCC2) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Furosemide is a loop diuretic that blocks the Na-K-2Cl symporter on the apical membrane of thick ascending limb cells, preventing reabsorption of approximately 20-30% of filtered sodium and chloride. This increases urine output and reduces fluid volume, lowering blood pressure and reducing edema. At low doses, the diuretic effect is modest while maintaining better electrolyte balance than standard doses.
Approved indications
- Edema associated with congestive heart failure
- Edema associated with hepatic cirrhosis
- Edema associated with renal disease
- Hypertension
Common side effects
- Hypokalemia
- Hyperuricemia
- Ototoxicity (at high doses)
- Dehydration
- Hypotension
- Hyperglycemia
- Hyponatremia
Key clinical trials
- Platform of Randomized Adaptive Clinical Trials in Critical Illness (NA)
- Effect of Short-Term Prednisone Therapy on C-Reactive Protein Change in Emergency Department Patients With Acute Heart Failure and Elevated Inflammatory Markers ( CORTAHF ) (PHASE2, PHASE3)
- Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts (PHASE4)
- Low Dose Continuous Furosemide Effect on Cardiac Surgery Patients With Kidney Dysfunction (PHASE2)
- Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients (PHASE1, PHASE2)
- Short-term Efficacy of Furosemide, Isosorbide Dinitrate and Their Combination in ADHF (NA)
- Orthostatic Hypotension Treatment on Rehab Unit (NA)
- OUTpatient Intravenous LASix Trial in Reducing Hospitalization for Acute Decompensated Heart Failure (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Low-dose furosemide CI brief — competitive landscape report
- Low-dose furosemide updates RSS · CI watch RSS
- Larissa University Hospital portfolio CI